Pattern of Failure and Treatment Results in Triple Negative Breast Cancer Patients

乳腺癌(英文) Pub Date : 2022-01-01 DOI:10.4236/abcr.2022.112006

S. Zawawy, G. Khedr

{"title":"Pattern of Failure and Treatment Results in Triple Negative Breast Cancer Patients","authors":"S. Zawawy, G. Khedr","doi":"10.4236/abcr.2022.112006","DOIUrl":null,"url":null,"abstract":"Non metastatic patients (n=108) had median follow up duration of 3.5 years. 21.3% patients developed relapse with median time to relapse of 11 months. 78.3% of relapsed patients had visceral (88.3% lung) metastasis, 13% bone metastasis, 21.7% brain metastasis and 13% LRR. Predictor for relapse: Significantly high risk of relapse in patients with large tumor size [T4: 66.75%, T3: 22.9%, T2:16.7%, T1: 0% (p= 0.002)], positive LNs [N3: 100%, N2: 37.9%, N1: 15.1%, N0: 4.3% (p <0.001)] and Ki67 [> 20: 31.6% versus 10.8% for Ki67≤ 20 (P =0.007)]. Multivariate analysis revealed only T4 and N2-3 were significantly associated with high probability for relapse (P = 0.022 & 0.038, respectively). Tumor grade I 1(0.9) 0 1(0.8) II 41(38.0) 7(35.0) 48(37.5) III 66(61.1) 13(65.0) 79(61.7) histopathology IDC 94(87.1) 13(65.0) 107(83.6) ILC 8(7.4) 1(5.0) 9(7.0) Others 6(5.5) 6(30.0) 12(9.4) surgery MRM 71(65.7) 0 BCS 37(34.3) 0 ALND 100(92.6) 0 SLN 8(7.4) 0 Neo adjuvant chemotherapy 34/108 (31.5%) CR 6(17.6%) PR 24(70.6%) No response 4(11.8%) Types of chemotherapy FAC 14(12.9%) 14 (11%) AC and Taxol 94(87%) 20 (100%) 114 (89%) Platinum/Gem 0(0%) 20(100%) 20(15.6%) Taxotere 0(0%) 12(60%) Xeloda 0(0%) 6(30%) Adjuvant XRT NO 10(9.3%) 20 (100%) 30(23.4%) conventional 56(51.8%) 0 56(43.8%) hypofractionation 42(38.9%) 0 42(32.8%) K. M Curve for DFS among non metastatic TNBC.","PeriodicalId":67095,"journal":{"name":"乳腺癌(英文)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"乳腺癌(英文)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/abcr.2022.112006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Non metastatic patients (n=108) had median follow up duration of 3.5 years. 21.3% patients developed relapse with median time to relapse of 11 months. 78.3% of relapsed patients had visceral (88.3% lung) metastasis, 13% bone metastasis, 21.7% brain metastasis and 13% LRR. Predictor for relapse: Significantly high risk of relapse in patients with large tumor size [T4: 66.75%, T3: 22.9%, T2:16.7%, T1: 0% (p= 0.002)], positive LNs [N3: 100%, N2: 37.9%, N1: 15.1%, N0: 4.3% (p <0.001)] and Ki67 [> 20: 31.6% versus 10.8% for Ki67≤ 20 (P =0.007)]. Multivariate analysis revealed only T4 and N2-3 were significantly associated with high probability for relapse (P = 0.022 & 0.038, respectively). Tumor grade I 1(0.9) 0 1(0.8) II 41(38.0) 7(35.0) 48(37.5) III 66(61.1) 13(65.0) 79(61.7) histopathology IDC 94(87.1) 13(65.0) 107(83.6) ILC 8(7.4) 1(5.0) 9(7.0) Others 6(5.5) 6(30.0) 12(9.4) surgery MRM 71(65.7) 0 BCS 37(34.3) 0 ALND 100(92.6) 0 SLN 8(7.4) 0 Neo adjuvant chemotherapy 34/108 (31.5%) CR 6(17.6%) PR 24(70.6%) No response 4(11.8%) Types of chemotherapy FAC 14(12.9%) 14 (11%) AC and Taxol 94(87%) 20 (100%) 114 (89%) Platinum/Gem 0(0%) 20(100%) 20(15.6%) Taxotere 0(0%) 12(60%) Xeloda 0(0%) 6(30%) Adjuvant XRT NO 10(9.3%) 20 (100%) 30(23.4%) conventional 56(51.8%) 0 56(43.8%) hypofractionation 42(38.9%) 0 42(32.8%) K. M Curve for DFS among non metastatic TNBC.

查看原文本刊更多论文

三阴性乳腺癌患者的失败模式和治疗结果

非转移性患者(n=108)的中位随访时间为3.5年。21.3%的患者复发，中位复发时间为11个月。78.3%的复发患者有内脏转移(88.3%)、骨转移(13%)、脑转移(21.7%)和LRR(13%)。复发预测因素:肿瘤大小较大的患者复发风险显著增高[T4: 66.75%， T3: 22.9%， T2:16.7%， T1: 0% (p= 0.002)]，阳性LNs [N3: 100%， N2: 37.9%， N1: 15.1%， N0: 4.3% (p: 31.6%， Ki67≤20的患者为10.8% (p= 0.007)]。多因素分析显示，只有T4和N2-3与高复发概率有显著相关性(P分别为0.022和0.038)。肿瘤I级1(0.9)0 1(0.8)II级41(38.0)7(35.0)48(37.5)III级66(61.1)13(65.0)13(65.0)79(61.7)组织病理学IDC 94(87.1) 13(65.0) 107(83.6) ILC 8(7.4) 1(5.0) 9(7.0)其他6(5.5)6(30.0)9(9.4)手术MRM 71(65.7) 0 BCS 37(34.3) 0 ALND 100(92.6) 0 SLN 8(7.4) 0 Neo辅助化疗34/108 (31.5%)CR 6(17.6%) PR 24(70.6%)无反应4(11.8%)化疗类型FAC 14(12.9%) 14(11%) AC和Taxol 94(87%) 20(100%) 114 (89%) Platinum/Gem 0(0%) 20(100%) 20(15.6%) taxoere 0(0%) 12(60%) Xeloda0(0%) 6(30%)辅助XRT NO 10(9.3%) 20(100%) 30(23.4%)常规56(51.8%)0.56(43.8%)低分割42(38.9%)0.42 (32.8%)k - M曲线非转移性TNBC的DFS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

乳腺癌(英文)

自引率

0.00%

发文量